Show simple item record

dc.contributor.authorVåtsveen, Thea Kristin
dc.contributor.authorMyhre, Marit Renee
dc.contributor.authorSteen, Chloe Beate
dc.contributor.authorWälchli, Sébastien
dc.contributor.authorLingjærde, Ole Christian
dc.contributor.authorBai, Baoyan
dc.contributor.authorDillard, Pierre
dc.contributor.authorTheodossiou, Theodossis
dc.contributor.authorHolien, Toril
dc.contributor.authorSundan, Anders
dc.contributor.authorInderberg, Else Marit
dc.contributor.authorSmeland, Erlend B
dc.contributor.authorMyklebust, June
dc.contributor.authorOksvold, Morten Pedersen
dc.identifier.citationJournal of Hematology & Oncology. 2018, 11:23 1-12.nb_NO
dc.description.abstractBackground Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified as a growth suppressor in some cancer types and was tested as a new treatment option in B-cell lymphoma. Methods We included artesunate in a cancer sensitivity drug screen in B lymphoma cell lines. The preclinical properties of artesunate was tested as single agent in vitro in 18 B-cell lymphoma cell lines representing different histologies and in vivo in an aggressive B-cell lymphoma xenograft model, using NSG mice. Artesunate-treated B lymphoma cell lines were analyzed by functional assays, gene expression profiling, and protein expression to identify the mechanism of action. Results Drug screening identified artesunate as a highly potent anti-lymphoma drug.Artesunate induced potent growth suppression in most B lymphoma cells with an IC50 comparable to concentrations measured in serum from artesunate-treated malaria patients, while leaving normal B-cells unaffected. Artesunate markedly inhibited highly aggressive tumor growth in a xenograft model. Gene expression analysis identified endoplasmic reticulum (ER) stress and the unfolded protein response as the most affected pathways and artesunate-induced expression of the ER stress markers ATF-4 and DDIT3 was specifically upregulated in malignant B-cells, but not in normal B-cells. In addition, artesunate significantly suppressed the overall cell metabolism, affecting both respiration and glycolysis. Conclusions Artesunate demonstrated potent apoptosis-inducing effects across a broad range of B-cell lymphoma cell lines in vitro, and a prominent anti-lymphoma activity in vivo, suggesting it to be a relevant drug for treatment of B-cell lymphoma.nb_NO
dc.publisherBMC (part of Springer Nature)nb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleArtesunate shows potent anti-tumor activity in B-cell lymphomanb_NO
dc.title.alternativeArtesunate shows potent anti-tumor activity in B-cell lymphomanb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.source.journalJournal of Hematology & Oncologynb_NO
dc.description.localcode© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
cristin.unitnameInstitutt for klinisk og molekylær medisin

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal